Transdermal Metformin Therapy (TMT) is a novel delivery method that provides the benefits of oral Metformin therapy, while reducing or eliminating the side effects associated with oral administration.
The U.S. Food and Drug Administration is announcing today that agency laboratory testing has revealed levels of the nitrosamine impurity N-Nitrosodimethylamine (NDMA) above the agency’s acceptable intake limit in several lots of the extended-release (ER) formulation of metformin